Review Article
Tailored Extracellular Vesicles: Novel Tool for Tissue Regeneration
Table 3
Modified EVs in the therapy of lung diseases.
| Diseases | EV Sources | Specific substrates | Modification methods | Modified EVs | Biological effects | Ref. |
| ALI | BMSC | miR-30b-3p | Cell transfection | miR-30b-3p-EV | Anti-inflammation more effectively | [66] | ALI | Platelet | DEX | Incubation | DEX-EV | Targeted delivery and less side effects | [68] | ALI | HEK293 cells | Curcumin; RBP | Incubation; fuse targeted peptides (RBP) with LAMP2B | RBP-EV | Targeted delivery and increased therapeutic effect | [69] | COVID-19 | Ginger derived lipid vesicles | miR396a-5p or rlcv-miRrL1-28-3p | Incubation | miRNA-EV | Remarkably suppressed inflammation and cytopathic effect | [73] | COVID-19 | HEK-293T cells | SiRNA-GFP; RBD | Electroporation; cell transfection with RBD-VSVG fusion vector | SiRNA-GFP-RBD-EV | Targeted delivery | [74] | COVID-19 | HEK-293T cells | PM targeting sequence | Fuse PM targeting sequence with ACE2 | PM-ACE2-EVs | Increase the accumulation of ACE2 on EV and block the interaction of virus with cells | [75] | IPA | Fibroblast cell | CLD-loaded liposomes | Hybrid nanovesicles | CLD-hybrid nanovesicles | Targeted delivery of antifibrotic drug with high efficiency | [82] | AA | M2 macrophage | Dnmt3aossmart silencer; PLGA nanoparticles | Synthetic EV-like nanocomplex | EV membrane coated Dnmt3aossmart silencer | Increase nanocomplex stability; targeted delivery of nucleic acid | [86] |
|
|